Imperial College London
Portrait Picture

ProfessorJenniferQuint

Faculty of Medicine, School of Public Health

Professor of Respiratory Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 8821j.quint

 
 
//

Location

 

.922Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Janson:2020:10.1007/s12325-020-01233-0,
author = {Janson, C and Menzies-Gow, A and Nan, C and Nuevo, J and Papi, A and Quint, J and Quirce, S and Vogelmeier, C},
doi = {10.1007/s12325-020-01233-0},
journal = {Advances in Therapy},
pages = {1124--1135},
title = {SABINA: an overview of short-acting β2-agonist use in asthma in European countries},
url = {http://dx.doi.org/10.1007/s12325-020-01233-0},
volume = {37},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - IntroductionGlobally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed to describe the current burden of SABA use among European individuals with asthma within the SABA use IN Asthma (SABINA) program.MethodsPrescription and/or dispensing data during 2006–2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year.ResultsMore than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55–64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9–32%) and moderate-to-severe (8–31%) asthma in the other European countries.ConclusionsThe findings of this study from the SABINA program show that SABA overu
AU  - Janson,C
AU  - Menzies-Gow,A
AU  - Nan,C
AU  - Nuevo,J
AU  - Papi,A
AU  - Quint,J
AU  - Quirce,S
AU  - Vogelmeier,C
DO  - 10.1007/s12325-020-01233-0
EP  - 1135
PY  - 2020///
SN  - 0741-238X
SP  - 1124
TI  - SABINA: an overview of short-acting β2-agonist use in asthma in European countries
T2  - Advances in Therapy
UR  - http://dx.doi.org/10.1007/s12325-020-01233-0
UR  - https://link.springer.com/article/10.1007%2Fs12325-020-01233-0
UR  - http://hdl.handle.net/10044/1/77002
VL  - 37
ER  -
Download